Proteostasis Therapeutics Inc (PTI) Expected to Post Quarterly Sales of $980,000.00

Share on StockTwits

Wall Street brokerages expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to post $980,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Proteostasis Therapeutics’ earnings, with the highest sales estimate coming in at $1.00 million and the lowest estimate coming in at $950,000.00. Proteostasis Therapeutics reported sales of $1.62 million in the same quarter last year, which indicates a negative year-over-year growth rate of 39.5%. The business is expected to report its next quarterly earnings report on Wednesday, March 13th.

According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year sales of $3.82 million for the current year, with estimates ranging from $3.79 million to $3.84 million. For the next fiscal year, analysts anticipate that the business will report sales of $3.70 million, with estimates ranging from $3.50 million to $3.89 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Proteostasis Therapeutics.

Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings results on Tuesday, November 6th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.04). The firm had revenue of $1.06 million for the quarter, compared to analysts’ expectations of $0.83 million. Proteostasis Therapeutics had a negative return on equity of 104.17% and a negative net margin of 1,307.84%.

PTI has been the subject of a number of recent analyst reports. Royal Bank of Canada upgraded shares of Proteostasis Therapeutics from a “sector perform” rating to an “outperform” rating in a report on Thursday, October 18th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Proteostasis Therapeutics in a report on Thursday, October 18th. ValuEngine upgraded shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, October 18th. Zacks Investment Research upgraded shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a report on Tuesday, October 23rd. Finally, Piper Jaffray Companies initiated coverage on shares of Proteostasis Therapeutics in a report on Monday, October 29th. They issued an “overweight” rating and a $14.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $12.80.

In related news, insider Meenu Chhabra sold 16,478 shares of the business’s stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $2.99, for a total value of $49,269.22. Following the completion of the sale, the insider now directly owns 97,093 shares in the company, valued at $290,308.07. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 19.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PTI. Meeder Asset Management Inc. purchased a new stake in Proteostasis Therapeutics during the fourth quarter worth approximately $37,000. Bank of Montreal Can grew its stake in Proteostasis Therapeutics by 8,649.2% during the fourth quarter. Bank of Montreal Can now owns 15,486 shares of the company’s stock worth $51,000 after buying an additional 15,309 shares during the period. JGP Global Gestao de Recursos Ltda. purchased a new stake in Proteostasis Therapeutics during the fourth quarter worth approximately $64,000. New York State Common Retirement Fund grew its stake in Proteostasis Therapeutics by 6,175.0% during the fourth quarter. New York State Common Retirement Fund now owns 25,100 shares of the company’s stock worth $81,000 after buying an additional 24,700 shares during the period. Finally, Rhumbline Advisers grew its stake in Proteostasis Therapeutics by 70.3% during the fourth quarter. Rhumbline Advisers now owns 36,418 shares of the company’s stock worth $118,000 after buying an additional 15,030 shares during the period. Institutional investors own 63.21% of the company’s stock.

Shares of NASDAQ PTI traded up $0.12 during midday trading on Wednesday, reaching $3.21. 688,224 shares of the stock were exchanged, compared to its average volume of 817,983. Proteostasis Therapeutics has a 52-week low of $1.71 and a 52-week high of $10.38.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.

Read More: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply